Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-793-9 | CAS number: 151-56-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- August - November 1973
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Guideline study, well documented and acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 975
- Report date:
- 1975
Materials and methods
- Principles of method if other than guideline:
- The study was conducted according to FDA Guidelines: "Guidelines for reproduction studies for safety evaluation of drugs for human use", Food and Drug Administration, Washington, January 1966.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Ethylenimine
- IUPAC Name:
- Ethylenimine
- Details on test material:
- - Name of test material (as cited in study report): Aethylenimin
- Physical state: liquid
- Analytical purity: 100 % (stabilised by NaOH)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: WIGA, Sulzfeld
- Age at study initiation: no data
- Weight at study initiation: no data
- Housing: 2 animals/cage
- Diet (ad libitum): Altromin-R (Altrogge, Lage/Lippe)
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 2
- Humidity (%): 55 ± 5
- Photoperiod (hrs dark / hrs light): 12 h / 12 h
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on exposure:
- VEHICLE
- pH: 7.0
- Amount of vehicle (if gavage): 500 µL/100 g animal - Analytical verification of doses or concentrations:
- no
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: no data
- Length of cohabitation: 12 hours
- Verification of same strain and source of both sexes: yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy - Duration of treatment / exposure:
- Day 6 to 15 of pregnancy
- Frequency of treatment:
- daily
- Duration of test:
- 20 days
Doses / concentrations
- Remarks:
- Doses / Concentrations:
3.1 and 1.24 µL/kg bw (corresponding to approx. 2.57 and 1.03 mg/kg bw) (Recalculation based on relative density at 24 °C = 0.83)
Basis:
actual ingested
- No. of animals per sex per dose:
- Dose group 1 (2.57 mg/kg bw): 34 females;
Dose group 2 (1.03 mg/kg bw): 23 females;
Control group 1 (untreated): 26 females;
Control group 2 (untreated): 17 females - Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: based on acute oral gavage toxicity study
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: daily
BODY WEIGHT: Yes
- Time schedule for examinations: 3 times/week
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: gross-pathologically (organs not specified)
- Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of medium late resorptions: Yes
- Number of late resorptions: Yes
- Placenta weight: Yes - Fetal examinations:
- - Fetal body length and weight: Yes: all per litter
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: 1/3 per litter
- Skeletal examinations: Yes: 2/3 per litter
- Head examinations: No - Statistics:
- Analysis of variance, t-test, and Chi-square-test (* >= 95 %, ** >= 99 %, compared to the untreated control)
- Indices:
- no data
- Historical control data:
- no data
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:yes
Details on maternal toxic effects:
Several rats of the high dose group showed vaginal bleeding. 2 aborts occurred. Body weights were reduced in this test group as compared to the control. The animals of the low dose group remained without clinical signs of toxicity. No mortality occurred after oral administration of the test substance. In the untreated control groups no clinical signs of toxicity and lethality were observed.
Effect levels (maternal animals)
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1.03 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:yes
Details on embryotoxic / teratogenic effects:
At the high dose level the percentage of living fetuses based on the number of implantations was decreased, and the number of dead implantations increased compared to the untreated control. Mean weight and length of the fetuses was reduced in the high dose group. The incidence of skeletal and organ malformations and retardations and variations was significantly increased compared to the control.
In the low dose group no embryolethal, fetotoxic or teratogenic effects were observed. The only effects noted were decrease of the mean length of the fetuses and of the mean placental weight.
Effect levels (fetuses)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1.03 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: teratogenicity
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 1.03 mg/kg bw/day (actual dose received)
- Basis for effect level:
- other: fetotoxicity
Fetal abnormalities
- Abnormalities:
- not specified
Overall developmental toxicity
- Developmental effects observed:
- not specified
Any other information on results incl. tables
Clinical symptoms:
In the group treated with 3.1 µL/kg bw of the substance 6 rats showed vaginal bleedings on day 14, 2 rats on day 15, 3 rats on day 14 and 15 and 1 rat on day 15 and 18 post coitum. 2 rats of this group had an abort.
The rats treated with 1.25 µL/kg bw of the substance as well as the control group showed no clinical symptoms.
Mortality:
There were no substance-related or spontaneous mortalities in any of the test groups.
Body weight:
Rats treated with 3.1 µL/kg bw of the test substance showed a decrease in body weight. 1.24 µL/kg bw had no effect.
Conception rate:
The rate of conceptions and implantations were not changed in animals treated with the test substance compared to the control groups.
Living fetuses:
The percentage of living fetuses based on the number of implantations was decreased in the dose group treated with 3.1 µL/kg bw of the test substance (40.24%) compared to the corresponding control group (96.61%). No significant change was observed in the dose group treated with 1.24 µL/kg bw (88.1%) compared to the corresponding control group (93.44%).
Dead implantations:
The number of dead implantations was significantly increased after application of 3.1 µL/kg bw of the test substance compared to the control. After application of 1.24 µL/kg bw of the test substance the number of dead implantations corresponds to the number in control animals.
Weight and length of the fetuses and weight of the placenta:
The mean weight of the fetuses was significantly reduced after application of 3.1 µL/kg bw of the test substance. Application of 1.24 µL/kg bw of the test substance had no effect.
The mean length of the fetuses was significantly reduced after application of 1.24 or 3.1 µL/kg bw of the test substance.
The mean placental weight was significantly reduced after application of 1.24 or 3.1 µL/kg bw of the test substance.
External examination of the fetuses:
1 fetus of the dosis group 1.24 µL/kg bw showed ectopia visceralis. In none of the other groups changes of the fetuses were observed.
Skeletal and organ examination:
After application of 3.1 µL/kg bw of the test substance 18 fetuses showed malformations. The number was significantly increased compared to the untreated control group. Most of the malformations observed were disruptions of vertebral bodies. 5 fetuses showed cleft palates, 3 fetuses showed hepatomegaly and 1 fetus buckled ribs. The incidence for retardations and variations was increased.
In the corresponding control group 4 fetuses showed malformations. Most of the malformations observed were disruptions of vertebral bodies. 1 fetus showed buckled ribs.
After application of 1.24 µL/kg bw of the test substance 3 fetuses showed malformations (disruptions of vertebral bodies). The percentage of malformations and the incidence for retardations and variations were not increased.
In the corresponding control 2 fetuses showed malformations (disruptions of vertebral bodies).
In conclusion, a dose of 3.1 µL/kg bw had a toxic effect on the rats and consequently an embryolethal and fetotoxic effect. The developmental toxic effects were also due to the toxic effect on the pregnant rats. A dose of 1.24 µL/kg bw of the test substance did not cause any clinical symptoms. No embryolethal, fetotoxic or teratogenic effects were observed at this dose level.
Parameter |
2.57 mg/kg bw |
Untreated control 1 |
1.03 mg/kg bw |
Untreated control 2 |
Pregnant dams/total dams |
34/34 |
27/28 |
23/23 |
17/23 |
Implantations/dam |
12.35 |
10.93 |
10.96 |
10.76 |
Living fetuses/dam |
4.97 |
10.56 |
9.65 |
10.06 |
Dead fetuses |
0 |
1 |
3 |
0 |
Early resorptions |
60 |
8 |
16 |
9 |
Medium late resorptions |
142 |
0 |
9 |
0 |
Late resorptions |
33 |
1 |
2 |
3 |
Dead implantations |
235** |
10 |
30 |
12 |
% dead implantations |
55.95 |
3.39 |
11.9 |
6.56 |
Abortions |
16 |
0 |
- |
- |
Mean fetal body weight |
2.39++ |
3.67 |
3.52 |
3.59 |
Mean fetal body length |
3.10++ |
3.65 |
3.58++ |
3.65 |
Placenta weight |
0.41++ |
0.56 |
0.48++ |
0.56 |
Runts |
161 |
5 |
4 |
1 |
Fetuses with malformations |
18** |
4 |
3 |
2 |
Skeletal malformations |
12 |
4 |
2 |
2 |
Soft tissue malformations |
8 |
0 |
1 |
0 |
* significance (chi-square-test) 95 %
** significance (chi-square-test) 99 %
+significance (t-test) 95 %
++significance (t-test) 99 %
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.